NexLife review
The rate set in the largest type belongs to a year-long plan, and the asterisk beside it says so.
The verdict
NexLife leads with compounded semaglutide as low as $119, footnoted as a twelve-month rate. Starting without that commitment costs $139. Tirzepatide begins at $169.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- Dose pricing
- Flat across doses
- From
- From $139/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- LegitScript
- Claimed by provider
NexLife sells both molecules by injection. It states LegitScript certification. Expedited shipping carries no charge.
Who writes the prescription, and what do they see?
NexLife calls itself a patient management platform, with clinicians prescribing where that is clinically appropriate. No clinician is named. What they examine before writing is not set out. The gap between platform and prescriber is worth noticing before a first order.
Each molecule has two rungs. The difference between them lives in a footnote rather than in a plan picker. Shipping is free and no membership sits beside either figure.
What happens when the dose goes up?
Flat pricing at every dose is stated for both molecules, so climbing the ladder leaves the bill alone. Who signs off on a step, and how fast, is not published. Against four months of escalation, a fixed figure is the more useful half of that pair.
What the price includes
A short plan costs $139 for semaglutide and $169 for tirzepatide. Reaching $119 or $139 takes a year of commitment. The gap is $20 a month on one molecule and $30 on the other. That gap is what the advertised figure costs in term length.
What it claims, and what it cites
Both lines are compounded rather than manufactured, prepared by a pharmacy NexLife does not identify. A compounded preparation is not reviewed by the FDA before it is dispensed.
Where it holds up, and where it does not
- Strength: The year-long condition sits in the footnote
- Strength: A shorter plan is genuinely offered
- Strength: One rate at every dose
- Strength: LegitScript certification stated
- Limitation: The advertised rate needs a full year
- Limitation: Starting without that commitment costs more
- Limitation: The compounding pharmacy goes unnamed
- Limitation: No state coverage list is published
What the evidence says about this kind of treatment
The assessment above is about NexLife. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A buyer settled on a year rather than testing a month.
- Wrong for
- A buyer unsure of lasting beyond a first quarter.
The evidence behind what NexLife prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How NexLife compares
| Seller | Who it suits | Go |
|---|---|---|
 Rx.com | Buyers ready to pay six months at once for the figure in the headline | See Rx.com → |
 RxPros | A reader able to fund a year at signing and collect deliveries by the quarter | See RxPros → |
 HeliMeds | Buyers converting a twelve-week plan into calendar months before comparing it | See HeliMeds → |
More GLP-1 telehealth sellers reviews: Mevo HealthMidi HealthMint MedMint Medical ClinicMochi HealthMojoon
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Can a new buyer pay $119 straight away?
- Only by taking the twelve-month plan. Without it the semaglutide rate is $139.
- What does tirzepatide cost?
- $169 on the shorter plan, or $139 across twelve months.
- Does a higher dose cost more?
- No. NexLife states the rate is flat at every dose, so escalation leaves the bill unchanged.
- Is NexLife expensive compared with other GLP-1 telehealth sellers?
- NexLife publishes a starting figure of $139/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NexLife below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.